Physician profile
Jared C Basham
NPI 1316907009
$2,537.09
in general payments reported to CMS, 2019-2025
27 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $237 · 2021: $11.39 · 2022: $13.70 · 2023: $97.50 · 2024: $516 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $383.52 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $303.19 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $234.38 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $234.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $184.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $163.64 | 2019-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.75 | 2019-2024 | Jardiance |
| Amgen INC. | $127.65 | 2019-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $115.12 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $69.38 | 2019-2024 | |
| Astellas Pharma US INC | $65.62 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $55.19 | 2019 | |
| Axsome Therapeutics, INC. | $52.00 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $46.93 | 2024-2025 | |
| Dynavax Technologies Corporation | $43.61 | 2023-2025 | Heplisav-B |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.45 | 2019 | |
| Exact Sciences Corporation | $36.89 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $36.80 | 2024-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $29.16 | 2024 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $28.37 | 2024 | Rexulti |
| Abbvie INC. | $26.13 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $23.95 | 2025 | Fanapt |
| Nalpropion Pharmaceuticals LLC | $21.68 | 2019 | |
| Allergan, INC. | $19.85 | 2020 | |
| Abbott Laboratories | $19.05 | 2024 | Freestyle Libre 3 |
| Shire North American Group INC | $16.14 | 2019 | |
| Inspire Medical Systems, INC. | $15.42 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Basham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.